Home LiteratureArticle Details
PMID: 18759107 Published · ppublish English

CHEK2 1100delC and male breast cancer in the Netherlands.

Breast cancer research and treatment ·Vol. 116 ·No. 2 ·2009-09-08

Wasielewski Marijke, den Bakker Michael A, van den Ouweland Ans, Meijer-van Gelder Marion E, Portengen Henk, Klijn Jan G M, Meijers-Heijboer Hanne, Foekens John A, Schutte Mieke

Abstract

Mutations in the breast cancer susceptibility genes BRCA1, BRCA2, and CHEK2 are known risk factors for female breast cancer. Mutations in BRCA1 and BRCA2 also are associated with male breast cancer (MBC). Similarly, it had been suggested in the original CHEK2 identification report that the CHEK2 1100delC mutation confers an increased risk for MBC. Here, we have evaluated the risk of CHEK2 1100delC for MBC by genotyping CHEK2 1100delC in 23 familial and 71 unselected Dutch MBC cases. None of the 23 familial MBC cases carried the CHEK2 1100delC mutation. In contrast, CHEK2 1100delC was present in 3 of the 71 (4.2%) unselected MBC cases, which was significantly more prevalent than the 1.1% Dutch population frequency assessed in 1,692 individuals (P = 0.05, OR = 4.1, 95% CI 1.2-14.3). Our data suggest that, in the Netherlands, CHEK2 1100delC is associated with an increased risk for MBC.

Article Info
Journal
Breast cancer research and treatment
Abbr.
Breast Cancer Res Treat
Published
2009-09-08
Indexed
2009-06-15
Updated
2013-11-21
Language
English
Country/Region
Netherlands
NLM ID
8111104
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com